Degen L, Petrig C, Studer D, Schroller S, Beglinger C
Department of Research and Clinical Research Center, University Hospital, Basel, Switzerland.
Neurogastroenterol Motil. 2005 Dec;17(6):821-6. doi: 10.1111/j.1365-2982.2005.00715.x.
Tegaserod is a novel selective serotonin receptor type-4 (5-HT(4)) partial agonist that stimulates gastrointestinal (GI) motility. Tegaserod has proven efficacy in irritable bowel syndrome with constipation in women and in men and women with chronic idiopathic constipation. The effects on gastric emptying, small bowel transit and colonic transit have not been studied in detail in male and female subjects. This study aimed therefore to assess the effect of gender on GI transit with and without tegaserod. A randomized, placebo-controlled, double-blind, crossover study was performed in 40 healthy subjects (23 males, 17 females). Each treatment period involved three and a half days of bid treatment with either 6 mg tegaserod or an identical placebo. Transit parameters were assessed by a scintigraphy. Tegaserod significantly accelerated gastric emptying, small bowel and colonic transit times (P<0.05-0.0001). The effect was more apparent in male subjects than in females (P=0.044 to P<0.0001). The most striking prokinetic effects were observed in the upper GI tract (stomach and small intestine). In both healthy male and female subjects, tegaserod markedly accelerated small intestinal transit, and induced a significant increase in gastric emptying time and colonic transit. The results imply that tegaserod is a potent prokinetic agent throughout the GI in both sexes.
替加色罗是一种新型的选择性5-羟色胺4型（5-HT(4)）受体部分激动剂，可刺激胃肠（GI）蠕动。替加色罗已被证实对女性便秘型肠易激综合征以及男性和女性慢性特发性便秘均有效。其对胃排空、小肠转运和结肠转运的影响在男性和女性受试者中尚未得到详细研究。因此，本研究旨在评估性别对使用和未使用替加色罗时胃肠转运的影响。对40名健康受试者（23名男性，17名女性）进行了一项随机、安慰剂对照、双盲、交叉研究。每个治疗期包括为期三天半的每日两次治疗，使用6毫克替加色罗或相同的安慰剂。通过闪烁扫描评估转运参数。替加色罗显著加速了胃排空、小肠和结肠转运时间（P<0.05 - 0.0001）。这种效果在男性受试者中比在女性中更明显（P = 0.044至P<0.0001）。最显著的促动力作用在上消化道（胃和小肠）中观察到。在健康男性和女性受试者中，替加色罗均显著加速了小肠转运，并使胃排空时间和结肠转运显著增加。结果表明，替加色罗在两性的整个胃肠道中都是一种有效的促动力剂。
